Millert-Kalińska, S.; Stawicka-Niełacna, M.; Tomczak, L.; Pruski, D.; Przybylski, M.; Jaszczyńska-Nowinka, K.; Poprawski, G.; Mądry, R.
Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice. Biomedicines 2025, 13, 483.
https://doi.org/10.3390/biomedicines13020483
AMA Style
Millert-Kalińska S, Stawicka-Niełacna M, Tomczak L, Pruski D, Przybylski M, Jaszczyńska-Nowinka K, Poprawski G, Mądry R.
Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice. Biomedicines. 2025; 13(2):483.
https://doi.org/10.3390/biomedicines13020483
Chicago/Turabian Style
Millert-Kalińska, Sonja, Małgorzata Stawicka-Niełacna, Lidia Tomczak, Dominik Pruski, Marcin Przybylski, Karolina Jaszczyńska-Nowinka, Grzegorz Poprawski, and Radosław Mądry.
2025. "Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice" Biomedicines 13, no. 2: 483.
https://doi.org/10.3390/biomedicines13020483
APA Style
Millert-Kalińska, S., Stawicka-Niełacna, M., Tomczak, L., Pruski, D., Przybylski, M., Jaszczyńska-Nowinka, K., Poprawski, G., & Mądry, R.
(2025). Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice. Biomedicines, 13(2), 483.
https://doi.org/10.3390/biomedicines13020483
